|
1
|
Liang Y, Zhu F, Zhang H, Chen D, Zhang X,
Gao Q and Li Y: Conditional ablation of TGF-β signaling inhibits
tumor progression and invasion in an induced mouse bladder cancer
model. Sci Rep. 6:294792016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Erlich A and Zlotta AR: Treatment of
bladder cancer in the elderly. Investig Clin Urol. 57 (Suppl
1):S26–S35. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
van den Bosch S and Alfred Witjes J:
Long-term cancer-specific survival in patients with high-risk,
non-muscle-invasive bladder cancer and tumour progression: A
systematic review. Eur Urol. 60:493–500. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pectasides D, Pectasides M and Nikolaou M:
Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder
cancer: Literature review. Eur Urol. 48:60–68. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Akand M, Kilic Ö, Harmankaya I, Karabagli
P, Yavas Ç and Ata Ö: Aggressive treatment for urothelial
cancer-complete urinary tract extirpation: Operative feasibility in
two cases. Turk J Urol. 45:393–397. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mathes J, Rausch S, Todenhöfer T and
Stenzl A: Trimodal therapy for muscle-invasive bladder cancer.
Expert Rev Anticancer Ther. 18:1219–1229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roberts JT, von der Maase H, Sengeløv L,
Conte PF, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine/cisplatin and
methotrexate/vinblastine/doxorubicin/cisplatin in patients with
locally advanced and metastatic bladder cancer. Ann Oncol. 17
(Suppl 5):v118–v122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Padma VV: An overview of targeted cancer
therapy. Biomedicine (Taipei). 5:192015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carter PJ: Potent antibody therapeutics by
design. Nat Rev Immunol. 6:343–357. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hoelder S, Clarke PA and Workman P:
Discovery of small molecule cancer drugs: Successes, challenges and
opportunities. Mol Oncol. 6:155–176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Imai K and Takaoka A: Comparing antibody
and small-molecule therapies for cancer. Nat Rev Cancer. 6:714–727.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mu Y and Sun D: Lapatinib, a dual
inhibitor of epidermal growth factor receptor (EGFR) and HER-2,
enhances radiosensitivity in mouse bladder tumor Line-2 (MBT-2)
cells in vitro and in vivo. Med Sci Monit. 24:5811–5819. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hänze J, Kessel F, Di Fazio P, Hofmann R
and Hegele A: Effects of multi and selective targeted tyrosine
kinase inhibitors on function and signaling of different bladder
cancer cells. Biomed Pharmacother. 106:316–325. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yan J, Risacher SL, Shen L and Saykin AJ:
Network approaches to systems biology analysis of complex disease:
Integrative methods for multi-omics data. Brief Bioinform.
19:1370–1381. 2018.PubMed/NCBI
|
|
16
|
Tyagi A, Chandrasekaran B, Kolluru V, Rai
S, Jordan AC, Houda A, Messer J, Ankem M, Damodaran C and Haddad A:
Combination of androgen receptor inhibitor and cisplatin, an
effective treatment strategy for urothelial carcinoma of the
bladder. Urol Oncol. 37:492–502. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pal D, Tyagi A, Chandrasekaran B, Alattasi
H, Ankem MK, Sharma AK and Damodaran C: Suppression of Notch1 and
AKT mediated epithelial to mesenchymal transition by Verrucarin J
in metastatic colon cancer. Cell Death Dis. 9:7982018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bellmunt J, Powles T and Vogelzang NJ: A
review on the evolution of PD-1/PD-L1 immunotherapy for bladder
cancer: The future is now. Cancer Treat Rev. 54:58–67. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sundararajan S and Vogelzang NJ: Anti-PD-1
and PD-L1 therapy for bladder cancer: What is on the horizon?
Future Oncol. 11:2299–2306. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Deng J, Peng M, Wang Z, Zhou S, Xiao D,
Deng J and Yang X, Peng J and Yang X: Novel application of
metformin combined with targeted drugs on anticancer treatment.
Cancer Sci. 110:23–30. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagaoka K, Fujii K, Zhang H, Usuda K,
Watanabe G, Ivshina M and Richter JD: CPEB1 mediates
epithelial-to-mesenchyme transition and breast cancer metastasis.
Oncogene. 35:2893–2901. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Grudzien-Nogalska E, Reed BC and Rhoads
RE: CPEB1 promotes differentiation and suppresses EMT in mammary
epithelial cells. J Cell Sci. 127:2326–2338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen Y, Tsai YH and Tseng SH: Regulation
of the expression of cytoplasmic polyadenylation element binding
proteins for the treatment of cancer. Anticancer Res. 36:5673–5680.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Burns DM and Richter JD: CPEB regulation
of human cellular senescence, energy metabolism, and p53 mRNA
translation. Genes Dev. 22:3449–3460. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Putoczki TL, Thiem S, Loving A, Busuttil
RA, Wilson NJ, Ziegler PK, Nguyen PM, Preaudet A, Farid R, Edwards
KM, et al: Interleukin-11 is the dominant IL-6 family cytokine
during gastrointestinal tumorigenesis and can be targeted
therapeutically. Cancer Cell. 24:257–271. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ernst M and Putoczki TL: Targeting IL-11
signaling in colon cancer. Oncotarget. 4:1860–1861. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Johnstone CN, Chand A, Putoczki TL and
Ernst M: Emerging roles for IL-11 signaling in cancer development
and progression: Focus on breast cancer. Cytokine Growth Factor
Rev. 26:489–498. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu D, Tao J, Ding J, Qu P, Lu Q and Zhang
W: Interleukin-11, an interleukin-6-like cytokine, is a promising
predictor for bladder cancer prognosis. Mol Med Rep. 7:684–688.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Khajah MA, Mathew PM and Luqmani YA:
Na+/K+ ATPase activity promotes invasion of
endocrine resistant breast cancer cells. PLoS One. 13:e01937792018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang H, Zuo Y, Ding M, Ke C, Yan R, Zhan
H, Liu J, Wang W, Li N and Wang J: LASS2 inhibits growth and
invasion of bladder cancer by regulating ATPase activity. Oncol
Lett. 13:661–668. 2017. View Article : Google Scholar : PubMed/NCBI
|
